Browse Category

Stock Market News News 20 November 2025 - 24 November 2025

Exact Sciences (EXAS) Stock Today, November 24, 2025: Abbott Buyout Spread, Analyst Downgrades and UBS Target Hike

Exact Sciences (EXAS) Stock Today, November 24, 2025: Abbott Buyout Spread, Analyst Downgrades and UBS Target Hike

Dateline: November 24, 2025 Exact Sciences Corporation (NASDAQ: EXAS) stock is trading calmly near its takeover price today as Wall Street digests a flood of fresh analyst calls, legal scrutiny and local reaction to Abbott Laboratories’ multi‑billion‑dollar bid for the
Quantum Computing Inc (QUBT) Stock News Today: Analyst Upgrade, ‘Quantum First’ Tailwinds and a Volatile Week – November 23, 2025

Quantum Computing Inc (QUBT) Stock News Today: Analyst Upgrade, ‘Quantum First’ Tailwinds and a Volatile Week – November 23, 2025

Quantum Computing Inc (NASDAQ: QUBT) heads into the new trading week with fresh analyst support, a place on new “best quantum stocks” lists and lingering questions about valuation after another roller‑coaster stretch for the stock. QUBT stock snapshot for November
AST SpaceMobile (ASTS) Jumps as BlueBird 6 Launch Date Set and Special Meeting Begins – Key Updates for November 21, 2025

AST SpaceMobile (ASTS) Jumps as BlueBird 6 Launch Date Set and Special Meeting Begins – Key Updates for November 21, 2025

AST SpaceMobile, Inc. (NASDAQ: ASTS) is back in the spotlight today after announcing a firm launch date for its next‑generation BlueBird 6 satellite and convening a special shareholder meeting that could shape how the fast‑growing space‑to‑smartphone company pays its people
Abbott Laboratories (ABT) to Buy Exact Sciences in Up to $23 Billion Cancer Diagnostics Deal – All the Key News on November 20, 2025

Abbott Laboratories (ABT) to Buy Exact Sciences in Up to $23 Billion Cancer Diagnostics Deal – All the Key News on November 20, 2025

Abbott Laboratories (NYSE: ABT) shook the healthcare and medtech markets today, November 20, 2025, by announcing a definitive agreement to acquire cancer diagnostics specialist Exact Sciences Corporation (NASDAQ: EXAS) in an all‑cash transaction valuing the target at about $21 billion
1 36 37 38 39 40 46
Go toTop